fda compounded tirzepatide warning 2024 2025 confirms shortage is still over, gives compounders a grace period Beyond the Headlines: FDA Warning

P., Carreira, M

In my clinical experience, many patients who plateau on semaglutide see renewed progress after transitioning to tirzepatide, although individual results vary and treatment decisions should always be guided by a medical provider

For some, traditional methods like dieting and gym memberships provide the desired results, while others seek medical assistance to achieve their goals

Tirzepatide (Mounjaro, Zepbound) is a once-weekly subcutaneous injection approved by the FDA for type 2 diabetes management and chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW